1. Articles in category: Personalized Medicine

    1-24 of 55 1 2 3 »
    1. PRecISion Medicine for Children With Cancer

      PRecISion Medicine for Children With Cancer

      Conditions :   Childhood Cancer;   Childhood Solid Tumor;   Childhood Brain Tumor;   Childhood Leukemia;   Refractory Cancer;   Relapsed Cancer Intervention :   Diagnostic Test: Molecular profiling and drug testing Sponsors :   Sydney Children's Hospitals Network;   Children's Cancer Institute Australia;   Australia and New Zealand Children's Haematology and Oncology Group (ANZCHOG);   Garvan Institute of Medical Research;   German Cancer Research Center (DKFZ) Recruiting

      Read Full Article
    2. Emerging and investigational therapies for neuroblastoma.

      Emerging and investigational therapies for neuroblastoma.

      Expert Opin Orphan Drugs. 2017;5(4):355-368

      Authors: Applebaum MA, Desai AV, Glade Bender JL, Cohn SL

      Abstract INTRODUCTION: Treatment for children with clinically aggressive, high-risk neuroblastoma remains challenging. Less than 50% of patients with high-risk neuroblastoma will survive long-term with current therapies, and survivors are at risk for serious treatment-related late toxicities.

      Read Full Article
      Mentions: Treatment
    3. Deletion of 11q in neuroblastomas drives sensitivity to PARP inhibition.

      Deletion of 11q in neuroblastomas drives sensitivity to PARP inhibition.

      Clin Cancer Res. 2017 Aug 22;:

      Authors: Sanmartín E, Muñoz L, Piqueras M, Sirerol JA, Berlanga P, Cañete A, Castel V, Font de Mora J

      Abstract PURPOSE: Despite advances in multimodal therapy, neuroblastomas with hemizygous deletion in chromosome 11q (20-30%) undergo consecutive recurrences with poor outcome.

      Read Full Article
    4. Children's Hospital of Philadelphia to Lead New Pediatric Data Resource Center for Research in Childhood Cancer and Structural Birth Defects

      Children's Hospital of Philadelphia to Lead New Pediatric Data Resource Center for Research in Childhood Cancer and Structural Birth Defects

      PHILADELPHIA, Aug. 15, 2017 /PRNewswire-USNewswire/ -- The Center for Data Driven Discovery in Biomedicine at Children's Hospital of Philadelphia (CHOP) will lead a new, collaborative effort funded by the National Institutes of Health Common Fund to discover the causes of pediatric cancer...

      Read Full Article
    5. New Tumor Database Deployed to Battle Childhood Cancer at UC Santa Cruz

      New Tumor Database Deployed to Battle Childhood Cancer at UC Santa Cruz

      The Treehouse Childhood Cancer Initiative researchers at UC Santa Cruz Genomics Institute and the St. Baldrick's Foundation are making a 11,000+ tumor database available for use by all researchers in the pediatric cancer community and beyond in our continued battle to take childhood back from cancer. The database contains RNA-Seq gene expression data, as well as age, disease, and sex.

      Read Full Article
      Mentions: Genetics
    6. NCI-COG Pediatric MATCH Trial to Test Targeted Therapies

      NCI-COG Pediatric MATCH Trial to Test Targeted Therapies

      NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers Posted: July 24, 2017 240-760-6600 Credit: National Cancer Institute Today investigators at the National Cancer Institute (NCI) and the Children’s Oncology Group (COG) announced the opening of enrollment for a unique precision medicine clinical trial.

      Read Full Article
      Mentions: Treatment COG
    7. MOlecular Screening for CAncer Treatment Optimization (MOSCATO-01) in pediatric patients: A single institutional prospective molecular stratification trial.

      MOlecular Screening for CAncer Treatment Optimization (MOSCATO-01) in pediatric patients: A single institutional prospective molecular stratification trial.

      Clin Cancer Res. 2017 Jul 21;:

      Authors: Harttrampf AC, Lacroix L, Deloger M, Deschamps F, Puget S, Auger N, Vielh P, Varlet P, Balogh Z, Abbou S, Allorant A, Valteau-Couanet D, Sarnacki S, Galmiche L, Meurice G, Minard-Colin V, Grill J, Brugières L, Dufour C, Gaspar N, Michiels S, Vassal G, Soria JC, Geoerger B

      Read Full Article
      Mentions: Treatment
    8. NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers

      NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers

      The nationwide precision medicine trial will enroll children and adolescents with advanced cancers that haven’t responded to standard therapy to explore treatments targeted at specific genetic mutations.

      Read Full Article
      Mentions: Treatment COG
    9. Ignyta Receives FDA Orphan Drug Designation for Entrectinib for Treatment of NTRK Fusion-Positive Solid Tumors

      Ignyta Receives FDA Orphan Drug Designation for Entrectinib for Treatment of NTRK Fusion-Positive Solid Tumors

      SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to entrectinib for “treatment of NTRK fusion-positive solid tumors.” NTRK fusions are molecular alterations that occur in a broad variety of adult and pediatric solid tumor types. Entrectinib is the company’s investigational, orally available, CNS-active tyrosine kinase inh

      Read Full Article
      Mentions: Treatment ALK
    10. Precision Medicine in Pediatric Oncology: Translating Genomic Discoveries into Optimized Therapies.

      "Survival of children with cancers has dramatically improved over the past several decades.  This success has been achieved through improvement of combined modalities in treatment approaches, intensification of cytotoxic chemotherapy for those with high-risk disease and refinement of risk stratification incorporating novel biologic markers in addition to traditional clinical and histologic features. Advances in cancer genomics have shed important mechanistic insights on disease biology and have identified "driver" genomic alterations, aberrant activation of signaling pathways, and epigenetic modifiers that can be targeted by novel agents.  Thus, the recently described genomic and epigenetic landscapes of many childhood cancers have expanded the ...

      Read Full Article
    11. Results Indicate That Larotrectinib Is Effective as the First Novel Targeted Therapy to Show a Consistent Response across Multiple Tumor Types in Adult and Pediatric Patients

      Results Indicate That Larotrectinib Is Effective as the First Novel Targeted Therapy to Show a Consistent Response across Multiple Tumor Types in Adult and Pediatric Patients

      Larotrectinib (LOXO-101) has demonstrated consistent and durable antitumor activity in tropomyosin receptor kinase (TRK) fusion cancers across a wide range of patient ages and tumor types and was well tolerated by patients, according to results from three clinical trials presented today at the annual meeting of the American Society of Clinical Oncology in Chicago.

      Read Full Article
    12. ICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatments

      ICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatments

      Scientists from The Institute of Cancer Research, London, have been awarded £1.5 million by the charity Children with Cancer UK to advance precision medicine in the UK and improve cancer treatment for children and young adults.

      Read Full Article
      Mentions: Treatment
    13. Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.

      Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.

      Genome Med. 2017 Feb 10;9(1):15

      Authors: Duffy DJ, Krstic A, Halasz M, Schwarzl T, Konietzny A, Iljin K, Higgins DG, Kolch W

      Abstract BACKGROUND: Retinoid therapy is widely employed in clinical oncology to differentiate malignant cells into their more benign counterparts.

      Read Full Article
      Mentions: MYCN
    14. New assay shows promise to advance personalized therapy for cancer patients

      New assay shows promise to advance personalized therapy for cancer patients

      ( Elsevier Health Sciences ) The National Cancer Institute's NCI-MATCH (Molecular Analysis for Therapy Choice) is a large, ongoing clinical trial that matches tumors to therapies based on the tumor's genetic characteristics. A report in The Journal of Molecular Diagnostics confirms that the assay tailored for this trial is highly sensitive for detecting genetic mutations from a variety of tumor tissue and, for the first time, has been reproduced with accuracy by multiple clinical laboratories, laying the groundwork for future clinical utility.

      Read Full Article
      Mentions: Diagnostics
    15. Does using biomarker to select patients for Phase 1 trials improve efficacy?

      Does using biomarker to select patients for Phase 1 trials improve efficacy?

      "These results argue strongly for the enrichment of phase 1 clinical trials with biomarker selection for targeted therapies. However, rigid exclusion based on biomarkers that have not been proven clinically could prove counterproductive in some cases," the authors conclude."

      Read Full Article
    16. Neuroblastoma: A Tough Nut to Crack.

      "These advances have resulted in a growing population of long-term survivors of neuroblastoma. Examination of the late effects and second malignant neoplasms (SMNs) in both older generations of survivors and more recently treated survivors will inform both design of future trials and surveillance guidelines for long-term follow-up. As a consequence of advances in understanding of the biology of neuroblastoma, successful clinical trials, and refined understanding of the late effects and SMNs of survivors, the promise of precision medicine is becoming a reality for patients with neuroblastoma."

      Read Full Article
      Mentions: Treatment MYCN
    17. Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine.

      Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine.

      Paediatr Drugs. 2016 May 3;

      Authors: Maagdenberg H, Vijverberg SJ, Bierings MB, Carleton BC, Arets HG, de Boer A, Maitland-van der Zee AH

      Abstract It is well known that drug responses differ among patients with regard to dose requirements, efficacy, and adverse drug reactions (ADRs). The differences in drug responses are partially explained by genetic variation.

      Read Full Article
    18. UCLA Study Yields the Key to Effective Personalized Medicine

      "Unlike other approaches to personalized medicine currently being tested, PPM doesn’t require complex, time-consuming analysis of a patient’s genetic information or of the disease’s cellular makeup. Instead, it produces a personalized drug regimen based on information about a person’s phenotype — biological traits that could include anything from blood pressure to the size of a tumor or the health of a specific organ."

      Read Full Article
    19. Patients with Advanced Cancer Want to Know Their Genomics Test Results

      "An overwhelming majority of people with incurable cancer want to hear findings from DNA sequencing of their own tumors and normal cells, and to learn how those results may affect their health and treatment options, Dana Farber Cancer Institute scientists report.  The discovery highlights the need to improve patient education about genomics and to boost the resources available for the oncologists who interpret and present these findings to the patients."

      Read Full Article
      Mentions: Treatment Genetics
    20. Pediatrics Data Platform Announced at White House Precision Medicine Initiative

      “The ‘big data’ genomics revolution presents us with unprecedented opportunities to improve treatments for pediatric brain tumors, which are the leading cause of disease-related death in children,” said Phillip Storm, M.D., division chief of Neurosurgery at CHOP and the Center’s co-director.  CHOP’s commitment to PMI is the product of collaborative efforts in pediatric cancer research that include a national network of more than 15 leading hospitals, numerous industry partners, foundations, patients and their families. The Cavatica system is central to these efforts, integrating a cloud-based, open infrastructure with big data analytics so that researchers can leverage a ...

      Read Full Article
      Mentions: Genetics
    21. Foundation Medicine Announces First-Ever Public Release of Broad Pediatric Data From FoundationCORE™ to Accelerate the Development of Precision Medicine Strategies for Pediatric Cancers

      “One of the biggest impediments to progress in the field of childhood cancer is the paucity of genomic data available from patients at the time of disease relapse. These data are critical to defining comprehensive strategies to precisely treat relapsed disease, and more importantly, to prevent disease recurrence in the first place,” stated John M. Maris, M.D., Giulio D'Angio Endowed Professor of Pediatric Oncology at Children’s Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania. “The data being made available from Foundation Medicine will serve as a tremendous resource for the cancer research ...

      Read Full Article
    22. Unique Next Generation Sequencing-Based Panel Designed for Pediatric Cancer Research

      Unique Next Generation Sequencing-Based Panel Designed for Pediatric Cancer Research

      "Children’s Hospital Los Angeles (CHLA) and Thermo Fisher Scientific have agreed to develop a next-generation sequencing (NGS)-based panel designed specifically for pediatric cancer research. The assay would be CHLA’s first NGS panel designed to target biomarkers associated with childhood cancers.  The NGS panel under development is a unique targeted DNA and RNA sequencing-based research gene panel. Its results could lead to better understanding of the pathogenesis and future therapy of pediatric cancer patients. It will utilize Thermo Fisher’s Ion Torrent NGS platform and Ion AmpliSeq technology."

      Read Full Article
    1-24 of 55 1 2 3 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles